Ukraine health ministry accepts Valion Bio Entolimod dossier for regulatory review

Valion Bio, Inc.

Valion Bio, Inc.

VBIO

0.00
  • Ukraine’s Ministry of Health accepted Valion Bio’s Entolimod dossier for formal review under its regulatory equivalence pathway.
  • A decision could come in 45-60 days, leveraging prior US FDA review work, subject to information requests.
  • Entolimod targets acute radiation syndrome; the review is the first known allied-nation regulatory evaluation of the product.
  • Valion Bio cited manufacturing capacity of about 1,300,000 doses to support potential government stockpiling.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607220745PR_NEWS_USPR_____CL10030) on July 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.